Amphetamine

Federal SAMHSA and DOT drug testing panels mandate accurate amphetamine detection, making it a critical analyte in workplace drug testing programs, forensic toxicology investigations, clinical toxicology screening, pain management compliance monitoring, and substance abuse treatment programs. UTAK’s comprehensive drugs of abuse panels contain amphetamine in urine matrix at multiple cutoff concentration levels, supporting both immunoassay screening and GC-MS or LC-MS/MS confirmatory methods required by federal workplace testing guidelines. Stock and custom drugs of abuse QC solutions can incorporate related sympathomimetic amines such as methamphetamine, MDMA, and MDA, along with other controlled substances to support your laboratory’s comprehensive regulated and non-regulated QC programs.